Cargando…
CB2 Receptor Involvement in the Treatment of Substance Use Disorders
The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615453/ https://www.ncbi.nlm.nih.gov/pubmed/34827554 http://dx.doi.org/10.3390/biom11111556 |
_version_ | 1784604108522520576 |
---|---|
author | Navarrete, Francisco García-Gutiérrez, María S. Gasparyan, Ani Navarro, Daniela Manzanares, Jorge |
author_facet | Navarrete, Francisco García-Gutiérrez, María S. Gasparyan, Ani Navarro, Daniela Manzanares, Jorge |
author_sort | Navarrete, Francisco |
collection | PubMed |
description | The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine. In addition, the discovery of CB2r in brain areas that are part of the reward system supports the relevance of CB2r in the field of addiction. Interestingly, animal studies support that the CB2r regulates anxiety and depression behavioral traits. Due to its frequent comorbidity with neuropsychiatric disorders, these pharmacological actions may be of great interest in managing SUD. Preliminary clinical trials are focused on exploring the therapeutic potential of modulating CB2r in treating addictive disorders. These promising results support the development of new pharmacological tools regulating the CB2r that may help to increase the therapeutic success in the management of SUD. |
format | Online Article Text |
id | pubmed-8615453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86154532021-11-26 CB2 Receptor Involvement in the Treatment of Substance Use Disorders Navarrete, Francisco García-Gutiérrez, María S. Gasparyan, Ani Navarro, Daniela Manzanares, Jorge Biomolecules Review The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine. In addition, the discovery of CB2r in brain areas that are part of the reward system supports the relevance of CB2r in the field of addiction. Interestingly, animal studies support that the CB2r regulates anxiety and depression behavioral traits. Due to its frequent comorbidity with neuropsychiatric disorders, these pharmacological actions may be of great interest in managing SUD. Preliminary clinical trials are focused on exploring the therapeutic potential of modulating CB2r in treating addictive disorders. These promising results support the development of new pharmacological tools regulating the CB2r that may help to increase the therapeutic success in the management of SUD. MDPI 2021-10-20 /pmc/articles/PMC8615453/ /pubmed/34827554 http://dx.doi.org/10.3390/biom11111556 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Navarrete, Francisco García-Gutiérrez, María S. Gasparyan, Ani Navarro, Daniela Manzanares, Jorge CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title | CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title_full | CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title_fullStr | CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title_full_unstemmed | CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title_short | CB2 Receptor Involvement in the Treatment of Substance Use Disorders |
title_sort | cb2 receptor involvement in the treatment of substance use disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615453/ https://www.ncbi.nlm.nih.gov/pubmed/34827554 http://dx.doi.org/10.3390/biom11111556 |
work_keys_str_mv | AT navarretefrancisco cb2receptorinvolvementinthetreatmentofsubstanceusedisorders AT garciagutierrezmarias cb2receptorinvolvementinthetreatmentofsubstanceusedisorders AT gasparyanani cb2receptorinvolvementinthetreatmentofsubstanceusedisorders AT navarrodaniela cb2receptorinvolvementinthetreatmentofsubstanceusedisorders AT manzanaresjorge cb2receptorinvolvementinthetreatmentofsubstanceusedisorders |